The standard treatment for newly diagnosed Hodgkin lymphoma is a combination of four chemotherapy drugs: doxorubicin, bleomycin, vinblastine, and dacarbazine (abbreviated ABVD). However, despite this treatment, the cancer returns in some patients. This occurs more often in those with advanced stage disease (stage III or IV).
In this study, researchers are comparing the standard treatment of ABVD with a different treatment: the drugs doxorubicin, vinblastine, and dacarbazine (abbreviated AVD) plus another drug called brentuximab vedotin. Brentuximab vedotin is already approved by the U.S. Food and Drug Administration for treating Hodgkin lymphoma which persists despite other treatments. The hope is that this new regimen will be more effective than the standard treatment for reducing the risk of cancer recurrence in patients with advanced untreated Hodgkin lymphoma.
Brentuximab has two parts: one (an antibody) that attaches to a protein on the surface of cancer cells called CD30, and another (an anticancer drug called monomethyl auristatin E) that kills the cancer. Patients will be randomly assigned to receive either ABVD or brentuximab/AVD.